- Home
- NRK vs FBRX Comparison
NRK vs FBRX Comparison
Compare NRK & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRK | FBRX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 935.2M | 899.4M |
| IPO Year | 2002 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NRK | FBRX |
|---|---|---|
| Price | $10.67 | $76.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | 231.4K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.30 | $10.18 |
| 52 Week High | $10.80 | $77.20 |
Technical Indicators
Market Signals| Indicator | NRK | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.29 | 84.48 |
| Support Level | $10.59 | $26.51 |
| Resistance Level | $10.79 | $77.20 |
| Average True Range (ATR) | 0.10 | 0.18 |
| MACD | 0.04 | -1.16 |
| Stochastic Oscillator | 98.89 | 57.93 |
Price Performance
Historical ComparisonAbout NRK Nuveen New York AMT-Free Quality Municipal Income Fund
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.